Based on the successful results of RX-3117, which is a revolutionary ingested cancer fighting drug, there appears to be a number of pharmas that have taken notice - this was intimated during the webcast. Because of this interest in RX-3117, Rexahn is already in discussions with more than one pharma about a partnership - Rexahn hopes to release news about a possible partnership in the near future! Rexahn has already initiated human trials, and IMHO, should RX-3117 exhibit positive clinical trial result's going forward, this will completely revolutionize how cancerous cells are destroyed, and possibly negated the need for chemotherapy!
Sentiment: Strong Buy
Thank you for your contribution Stox- seems as if we are the same page here.
RNN is a great investment- but most importantly has a mircale drug pipeline that has the potential to save thousands of lives.
Let it be a friendly reminder to all looking for a multi-bagger, RNN is a LONG-TERM play.
Good luck to you all,
I know RNN is a speculative play. But there initial Phase 1 results on the 3 contenders are showing great promise to the Oncology community. Targeted cancer treatment without affecting healthy cells. Initial proof of concept has been proven already. Now they are on to safety trials for proper dosage. I think big pharmas are out there that are closely taking a look at Rexahn and the potential for multiple types of cancer treatment. I'm long RNN right now and could have sold today. But I think this puppy is going to have some legs to run this year with upcoming positive clinical data with 3117 and an impending partnernship with big pharma.
To the shorters, please continue to short and bash the stock price down. I'll be waiting to buy the dips and loading up. The more shorts, the more exciting the squeeze will be helping to catapult the stock price when news is announced. Go RNN!
Sentiment: Strong Buy
Same info that anyone who's been following the stock, already knows. There was nothing new today. Same pitch, same info. People are are mistaking today for a news update on clinical results. Today was not an update, it was a sales pitch to potential investors. That's it. Nothing more. So no reason to get excited and no reason to get scared off.